Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Australian Household Spending Dips in December as RBA Tightens Policy 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
SK pharmteco, a global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of SK Inc., just launched its second production plant in France. With this new facility, it has now increased its production of viral vectors to double.
The Korea Economic Daily, Yposkesi, an SK pharmteco's subsidiary and one of Europe's largest CDMOs for viral vector manufacturing in Cell and Gene Therapies, finished up the construction of the new 5,000 square meter facility for industrial bioproduction for cell and gene therapy.
It was added that Yposkesi is planning to launch the commercial operations of the vector factory in 2024. A total of $65.3 million was put in for the construction of this facility. The companies may now produce up to 75 batches of cell and gene therapy products per year.
These productions are said to be one of the most advanced personalized types of medicine for the treatment of rare disorders and serious illnesses. The demand for such treatments is growing as they were proven to be effective and with fewer side effects too. These give good results since they are made with patients' own genes and cells.
"It is with great pleasure and pride that today we open the new Yposkesi viral vector manufacturing facility. This twin site enables us to stay up to pace with demand by producing larger quantities of C> products approved for commercialization," Yposkesi's chief executive officer, Alain Lamproye, said in a press release. "The facility's state-of-the-art design will allow us, in collaboration with our clients, to manufacture advanced therapies more efficiently and cost-effectively in line with their C> pipelines and commitments, making these treatments more accessible to patients."
SK Inc. head of Bio Investment Center, Kim Yeon Tae Kim, also said they "anticipate Yposkesi to become a leading global Cell and Gene Therapy Contract Development and Manufacturing Organization through the synergy achieved with the Center for Breakthrough Medicines (CBM), a US-based cell and gene therapy CDMO and a subsidiary of SK pharmteco."
Photo by: SK Inc. Press Release
